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INTRODUCTION 
Diabetes mellitus (DM) is characterised by hyperglycaemia 
due to disturbances in the metabolism of carbohydrate, fat and 
protein because of abnormalities in the availability of insulin or 
insulin action (65). 
Currently number of diabetic patients in worldwide is 
estimated to be 150 millions, two third of which are residing in 
developing countries. The number is predicted to double by 2025, 
with the greatest number of cases in India and China alone.                                     
Even though diabetes mellitus is an endocrine disease in 
origin, its major manifestations are those of a metabolic disease. 
The characteristic symptoms are excessive thirst, polyuria, pruritus, 
and otherwise unexplained weight loss. The secondary 
complications of diabetes is due to the thickening of basement 
membrane.  
The most dominant feature of the metabolism in diabetes 
mellitus is an abnormally high concentration of blood glucose. This 
can be either due to an abnormally high rate of glucose production 
or of impaired glucose utilisation. It is now accepted that the high 
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blood glucose level is the result of combination of both of these 
processes.  
The secondary complications seen in diabetic patients are 
found to be due to alterations in vascular basement membrane 
composition as well as accumulation of glucose derived reaction 
products owing to over utilisation of glucose in insulin independent 
tissues [2]. 
Various authors have shown that hyperglycaemia leads to an 
increase in serum glycated proteins [3, 4, 5] along with alterations 
in other atherogenic risk factors. Disturbances in mineral 
metabolism are also noticed [6] and it is not known whether 
differences in trace element status are a consequence to the 
expression of the disease.  
Zn is an essential trace mineral directly involved in the 
physiology and action of insulin. Insulin is stored as Zn crystals in 
the β cells of the pancreas. It has been suggested that abnormal Zn 
metabolism may play a role in the pathogenesis of diabetes and 
some of its complications [27]. Zn depletion has several potential 
clinical implications. It is speculated that Zn repletion could 
improve insulin sensitivity in patients with DM and reduce the 
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severity of certain complications of this disease [28]. In order to 
understand the underlying patho biochemical inter-relationships of 
the late complications of diabetics in more detail, this study was 
undertaken. 
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AIMS & OBJECTIVES 
 To detect serum zinc level in patients with diabetes mellitus.  
 To compare the serum zinc level in newly diagnosed diabetic 
patients & in those with complications.  
 To find out the relationship between zinc deficiency & 
complications of diabetes. 
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REVIEW OF LITERATURE 
ZINC 
Zinc is the 24th most abundant element in the Earth's crust 
and has five stable isotopes. The element was probably named by 
the alchemist Paracelsus after the German word zinke. German 
chemist Andreas Sigismund Marggraf  is normally given credit for 
discovering pure metallic zinc in 1746. Work by Luigi 
Galvani and Alessandro Volta uncovered the electrochemical 
properties of zinc by 1800.  A variety of zinc compounds are 
commonly used, such as zinc carbonate and zinc gluconate (as 
dietary supplements), zinc chloride (in deodorants), zinc 
pyrithione (anti-dandruff shampoos), zinc sulfide (in luminescent 
paints), and zinc methyl or zinc diethyl in the organic laboratory. 
BIOCHEMICAL FUNCTIONS OF ZINC 
Zinc is an essential trace element, necessary for 
plants[29] animals and microorganisms. Zinc is found in nearly 100 
specific enzymes, serves as structural ions in transcription 
factors and is stored and transferred in metallothioneins. It is 
"typically the second most abundant transition metal in organisms" 
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after iron and it is the only metal which appears in all enzyme 
classes [29]. 
There are 2–4 grams of zinc distributed throughout the human 
body. Most zinc is in the brain, muscle, bones, kidney, and liver, 
with the highest concentrations in the prostate and parts of the eye. 
Semen is particularly rich in zinc, which is a key factor for prostate 
gland function and reproductive organ growth.  
Zinc plays ubiquitous biological roles in the prostate [34]. It 
interacts with a wide range of organic ligands[34] and has roles in 
the metabolism of RNA and DNA, signal transduction, and gene 
expression. It also regulates apoptosis.  
A 2006 study estimated that about 10% of human proteins 
(2800) potentially bind zinc, in addition to hundreds which 
transport and traffic zinc; similar to the Silico study in the plant 
 Arabidopsis thaliana which found  2367 zinc-related proteins[29].  
In the brain, zinc is stored in specific synaptic 
vesicles by glutaminergic  neurons [35] and can modulate brain 
excitability[34]. It plays a key role in  synaptic  plasticity and so in 
learning. However it has been called "the brain's dark 
horse"[39] since it also can be a  neurotoxin, suggesting that 
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zinc homeostasis plays a critical role in normal functioning of the 
brain and central nervous system. 
Zinc is an efficient  lewis acid, making it a useful catalytic 
agent in hydroxylation and other enzymatic reactions. The metal 
also has a flexible coordination geometry, which allows proteins 
using it to rapidly shift conformations  to perform biological 
reactions. Two examples of zinc-containing enzymes are carbonic 
anhydrase and carboxy peptidase, which are vital to the processes 
of carbon dioxide (CO2) regulation and digestion of proteins, 
respectively.  
In vertebrate blood, carbonic anhydrase converts CO2 into 
bicarbonate and the same enzyme transforms the bicarbonate back 
into CO2 for exhalation through the lungs. Without this enzyme, 
this conversion would occur about one million times slower at the 
normal blood pH of 7 or would require a pH of 10 or more.  
Carboxypeptidase cleaves peptide linkages during digestion of 
proteins. A coordinate covalent bond is formed between the 
terminal peptide and a C=O group attached to zinc, which gives the 
carbon a positive charge. This helps to create a hydrophobic pocket 
on the enzyme near the zinc, which attracts the non-polar part of 
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the protein being digested [39].Zinc also serves a purely structural 
role in zinc fingers twists and clusters[40].  
 METABOLISM OF ZINC 
In blood plasma, zinc is bound to and transported 
by albumin (60%, low-affinity) and transferrin (10%). Since 
transferrin also transports iron, excessive iron reduces zinc 
absorption, and vice-versa. A similar reaction occurs with 
copper. The concentration of zinc in blood plasma stays relatively 
constant regardless of zinc intake. Cells in the salivary gland, 
prostate, immune system and intestine use zinc signaling as a way 
to communicate with other cells [42].  
Zinc may be held in  metallothionein reserves within 
microorganisms or in the intestines or liver of animals. 
Metallothionein in intestinal cells is capable of adjusting absorption 
of zinc by 15–40%. However, inadequate or excessive zinc intake 
can be harmful; excess zinc particularly impairs copper absorption 
because metallothionein absorbs both metals. 
ZINC DEFICIENCY 
Hypozincemia is a condition where insufficient zinc is 
available for metabolic needs. 
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Prevalence 
In fact, one-third of the world population is at risk of zinc 
deficiency, ranging from 4 to 73% depending on the country. Zinc 
deficiency is the fifth leading risk factor for disease in the 
developing world. Providing micronutrients, including zinc, to 
humans is one of the four quick-win solutions to major global 
problems identified in the Copenhagen consensus from an 
international panel of distinguished economists. Conservative 
estimates suggest that 25% of the world's population is at risk for  
zinc deficiency[44] 
Causes 
Hypozincemia is usually a nutritional deficiency, but can also 
be associated with malabsorption, diarrhoea, acrodermatitis 
enteropathica, chronic  liver disease, chronic  renal disease, sickle 
cell diasease, diabetes, malignancy, and other chronic illnesses 
[45]. It can also occur after bariatric surgery. 
Zinc deficiency is typically the result of inadequate dietary 
intake of zinc, disease states that promote zinc losses, or 
physiological states that require increased zinc. Populations that 
consume primarily plant based diets that are low in bioavailable 
zinc often have zinc deficiencies [46] [47]. Diseases or conditions 
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that involve intestinal absorption promote zinc losses. Fecal losses 
of zinc caused by diarrhea is one contributing factor [55], often 
common in developing countries. Changes in intestinal tract 
absorbability and permeability due, in part, to viral, protozoal, and 
bacteria pathogens may also encourage fecal losses of 
zinc[49].Physiological states that require increased zinc include 
periods of growth in infants and children as well as in mothers 
during pregnancy[50].  
SIGNS AND SYMPTOMS 
Signs of zinc deficiency include hair loss,skin 
lesions, diarrhea, and wasting of body tissues. A lack of zinc can 
contribute to acne [51]. Vision[52][53], taste ,smell and memory 
are also connected with zinc. A deficiency in zinc can cause 
malfunctions of these organs and functions.  
One easily recognized sign which may be caused by zinc 
deficiency is white spots, bands, or lines on fingernails 
(leuconychia).An occasional white spot is an evidence that the 
immune system has overcome a bacterial or some other systemic 
infection. Some women may have multiple parallel white bands or 
lines on the fingernails marking menstrual cycles when marginal 
zinc deficiency was present.  
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Cognitive and motor function impairment 
Cognitive and motor function may also be impaired in zinc 
deficient children. Zinc deficiency can interfere with many organ 
systems especially when it occurs during a time of rapid growth and 
development, when nutritional needs are high, such as during  
infancy [57][43].  Low maternal zinc status has been associated 
with less attention during the neonatal period and worse motor 
functioning[59]. In some studies, supplementation has been 
associated with motor development in very low birth weight infants 
and more vigorous and functional activity in infants and 
toddlers[59]. 
Diarrhoea and pneumonia 
Zinc deficiency contributes to an increased incidence and 
severity of diarrhoea and pneumonia[48]. Studies have shown that 
zinc treatment results in 25 percent reduction in duration of acute 
diarrhoea and a 40 percent reduction in treatment failure or death in 
persistent diarrhoea[60]. Studies have found that a ten-day therapy 
of zinc treatment can considerably reduce the duration and severity 
of diarrheal episodes, decrease stool output, and lessen the need for 
hospitalization. Zinc may also prevent future diarrhoea episodes for 
up to three months. A zinc taste test  which finds out the taste 
 12
disturbances in an individual may have potential for diagnosing its 
deficiency [54]. 
Dysmenorrhoea 
High dose of zinc, 30 mg 1-3 times a day, 
prevents dysmenorrhoea[62] .  
Pregnancy 
Zinc deficiency during pregnancy can negatively affect both 
the mother and fetus. A review of pregnancy outcomes in women 
with acrodermatitis enteropathica, reported that out of every seven 
pregnancies, there was one abortion and two malfunctions, 
suggesting the human fetus is susceptible to the teratogenic effects 
of severe zinc deficiency. However, a review on zinc 
supplementation trials during pregnancy did not report a significant 
effect of zinc supplementation on neonatal survival. 
Effect of zinc on lymphoid and myeloid cells 
Thymulin, a thymic hormone, requires zinc for its 
activity[37][33]. In zinc deficiency, Th1 cytokines decrease, but 
Th2 cytokines are not affected. Thus, Th1 shifts to Th2 function. 
Zinc decreases the gene expression and  generation of TNF α, IL- 
1β,IL- 8 cytokines. 
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Treatment of zinc defeciency 
Zinc supplementation has been shown to reduce diarrhea 
prevalence and mortality in children younger than 5 years of age 
[64]. To combat zinc deficiency, five intervention strategies can be 
used: 
1) Supplementation using medicines 
2) Food fortification through the incorporation of zinc additives 
in food 
3) Dietary modification/diversification 
4) Genetic biofortification through plant breeding 
5) Agronomic biofortification through zinc fertilization. 
EFFECTS OF DIABETES ON ZINC METABOLISM 
Hypozincemia may be the result of hyperzincuria or 
decreased gastrointestinal absorption of Zn or both in diabetes. It 
appears the hyperzincuria, is a result more of hyperglycemia than of 
any specific effect of endogenous or exogenous insulin on the renal 
tubule.  Isbir et al demonstrated a 20% decrease in serum Zn (p < 
0.01) in Type I diabetes, apparently the result of hyperzincuria [7]. 
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El Yazigi et al evaluated both Type I and II diabetics and 
found that the absolute and creatinine corrected urinary  excretions 
were greater in diabetics than in matched controls and found a 
positive correlation between Zn excretion and hemoglobin Alc 
concentrations [8].       
In Type II Diabetes,insulin reduces the hyperzincuria while 
other agents had no effect on zinc excretion[9].                                                       
It has also been postulated that hyperglycemia interferes with 
the active transport of Zn back into the renal tubular cells. 
Administration of insulin reduces but does not appear to completely 
ameliorate the hyperzincuria [11][12]. 
McNair et al [13] confirmed that hyperzincuria occurs in 
relationship to the degree of hyperglycemia, but not glycosuria. 
Kinlaw et al [10] demonstrated abnormal Zn tolerance tests in 
diabetic patients suggestive of decreased absorption. 
Escobar also demonstrated a down regulation of fractional Zn 
transport in the gut and kidney which may be related to increased 
production of metallothionein in diabetics. Metallothionein is an 
intracellular cation binding protein which appears to act as an 
inhibitor of Zn transport. This decrease in gastrointestinal 
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absorption, coupled with hyperzincuria, could account for 
significant loss of intracellular Zn [14][13]. 
While it is clear that urinary excretion of Zn is markedly 
increased in individuals with diabetes, if hyperglycemia is the 
primary etiology, replacement with oral Zn supplementation should 
provide sufficient treatment[38].  
EFFECTS OF ZINC ON DIABETES MELLITUS (PRIMARY 
DISEASE EFFECTS) 
In 1966, Quarterman et al[15] demonstrated that diet induced 
zinc deficiency in rats resulted in a decrease in the ability of the 
pancreas to secrete insulin in response to a glucose load—a 
hallmark of diabetes.  
A few years later, Boquist et al [16] demonstrated a decrease 
in glucose tolerance with no change in insulin production in zinc 
deficient hamsters in response to an iv glucose load. They also 
demonstrated decreased granulation of the islet cell with both light 
and electron microscopy in zinc deficiency [16]. Since zinc is 
intrinsic to the storage granulization of insulin within the beta cell 
and increased insulin secretion reduces beta cell zinc concentration, 
these data are compatible with decreased islet cell insulin content in 
zinc deficiency states [17]. 
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Because zinc is a necessary factor in a variety of 
“antioxidant” enzymes, particularly superoxide dismutase, catalase 
and peroxidase, alterations of zinc metabolism such that adequate 
zinc is unavailable for these enzymes might be expected to 
contribute to the tissue damage observed in diabetes [18]. 
Rabinovitch et al [19] examined the relationship between 
cytokine induced (interleukin 1b, tumor necrotic factor (TNF) and 
interferon gamma) pancreatic beta cell destruction, production of  
malondialdehyde (MDA), an end product of lipid peroxidation, and 
nitrite, the end product of nitric oxide. These studies suggested  that 
cytokines are toxic to the human beta cell by producing oxygen free 
radicals, lipid peroxidation, and aldehyde production in the islets 
and that MDA was one of the cytotoxic mediators [18][19]. 
Other investigators have suggested that the Zn-
metallothionein complex in the islet cell provides protection against 
free radicals produced in the cell from any cause, and certainly the 
immune mediated cytokine provoked oxidative stress would be a 
significant oxidative stress. The more depleted the intracellular Zn 
stores, the less able the cell is to defend itself against this oxidative 
load[30]. This provides a potential mechanism for zinc deficiency 
to affect the progress of Type I diabetes.  
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Zimny et al have demonstrated induction of metallothionein 
production in the islet cell in response to  Streptozocin  (STZ) 
induced OH radical production [20]. Yang and Cherian [21] 
demonstrated STZ-induced lipid peroxidation and decreased 
superoxide dismutase (SOD). Roza showed marked decreases in 
pancreatic SOD and catalase antioxidant activity which preceded 
the loss of beta cell function suggesting increased beta cell 
vulnerability to free radical attack and cell destruction in 
genetically diabetic  rats [22]. All of these data suggest a role for 
Zn in the protection of the beta cell against the immune-mediated 
free radical attack.  
In Type II diabetes, there is no good evidence for oxidative 
stress as a major factor in the development of either insulin 
deficiency or islet cell damage, but there is clear evidence for 
increased secretion of insulin, at least early in the progress of the 
disease. Since Zn leaves the cell with insulin, the greater secretion 
of insulin causes cellular depletion of Zn. The cell can make more 
insulin, but it cannot make more Zn and, with hyperzincuria, the Zn 
co-secreted is more likely to be excreted and not available for re-
uptake into the cellular pool. With the slow loss of intracellular 
zinc, the less insulin is secreted for a given glucose level and the 
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islet cell becomes more vulnerable to all sorts of damage. This 
matches the clinical picture in which, after prolonged 
hyperglycemia and inability of the islet cell to make enough insulin 
to control the glucose, there is a loss of islet cell altogether. This 
provides a mechanism by which Zn deficiency may affect the 
progress of Type II diabetes [23]. 
EFFECTS OF ZINC ON DIABETES MELLITUS 
(SECONDARY COMPLICATIONS) 
It has become clear in recent years that hyperglycemia is a 
major culprit in the development of the microvascular 
complications which include retinopathy, nephropathy, neuropathy 
and the small vessel occlusions as well as birth defects including 
fetal malformations and macrosomia. It also appears clear that, 
while hyperglycemia is a major contributor, it is not the only 
contributor to the development of these complications. 
In mice made diabetic with STZ there was a marked increase 
in fetal loss and malformation as compared with nondiabetic mice. 
In similar, but transgenic mice for the human copper-zinc 
superoxide dismutase (Cu-Zn SOD), there were fewer fetal 
malformations than in controls without the gene suggesting SOD 
reduces diabetic embryopathy, presumably by reducing oxygen free 
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radicals [24]. In other animal studies Minami et al [25] 
demonstrated an increase in the progression of diabetic nephropathy 
in STZ diabetic rats when Zn deficiency was induced either by 
increased renal excretion or by dietary induced deficiency. 
In humans, Faure demonstrated some protective effect of Zn 
supplementation for the development of diabetic retinopathy 
associated with an increase in SOD. This suggested that the 
observed decrease in retinopathy may be the result of decreased 
lipid peroxidation of the retinal polyunsaturated fatty acids [26]. 
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DIABETES MELLITUS 
DEFINITION 
The term diabetes mellitus describes a metabolic disorder of 
multiple aetiology characterized by chronic hyperglycaemia with 
disturbances of carbohydrate, fat and protein metabolism resulting 
from defects in insulin secretion, insulin action[65], or both. The 
effects of diabetes mellitus include long–term damage, dysfunction 
and failure of various organs. 
SYMPTOMS AND SIGNS 
Diabetes mellitus may present with characteristic symptoms 
such as thirst, polyuria, blurring of vision, and weight loss. In its 
most severe forms, ketoacidosis or a non ketotic hyperosmolar state 
may develop and lead to stupor, coma and, in absence of effective 
treatment, death. Often symptoms are not severe, or may be absent, 
and consequently hyperglycaemia sufficient to cause pathological 
and functional changes may be present for a long time before the 
diagnosis is made. The long–term effects of diabetes mellitus 
include progressive development of the specific complications of 
retinopathy with potential blindness, nephropathy that may lead to 
renal failure, and/or neuropathy with risk of foot ulcers, 
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amputation, Charcot joints, and features of autonomic dysfunction, 
including sexual dysfunction. 
PATHOGENESIS OF DIABETES   
Several pathogenetic processes are involved in the 
development of diabetes. These include processes which destroy the 
beta cells of the pancreas with consequent insulin deficiency, and 
others that result in resistance to insulin action. The abnormalities 
of carbohydrate, fat and protein metabolism are due to deficient 
action of insulin on target tissues resulting from insensitivity or 
lack of insulin. The aetiological types designate defects, disorders 
or processes which often result in diabetes mellitus. 
TYPE 1 
Type 1 indicates the processes of beta–cell destruction [65] 
that may ultimately lead to diabetes mellitus in which insulin is 
required for survival to prevent the development of ketoacidosis, 
coma and death. An individual with a Type 1 process may be 
metabolically normal before the disease is clinically manifest, but 
the process of beta–cell destruction can be detected.  
Type 1 is usually characterized by the presence of anti–GAD, 
islet cell or insulin antibodies [67] which identify the autoimmune 
processes that lead to beta–cell destruction. In some subjects with 
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this clinical form of diabetes, particularly non–Caucasians, no 
evidence of an autoimmune disorder is demonstrable and these are 
classified as “Type 1 idiopathic”.  
TYPE 2 
It is due to predominant insulin resistance with relative 
insulin deficiency or predominant insulin secretory defect 
with/without insulin resistance[68]. Diabetes mellitus of this type 
was previously encompassed as non–insulin–dependent diabetes, or 
adult–onset diabetes. It is a term used for individuals who have 
relative (rather than absolute) insulin deficiency.  
People with this type of diabetes frequently are resistant to 
the action of insulin. At least initially, and often throughout their 
lifetime, these individuals do not need insulin treatment to survive. 
This form of diabetes is frequently undiagnosed for many years 
because the hyperglycaemia is often not severe enough to provoke 
noticeable symptoms of diabetes. Nevertheless, such patients are at 
increased risk of developing macro vascular and micro vascular 
complications [69]. 
The majority of patients with this form of diabetes are obese, 
and obesity itself causes or aggravates insulin resistance [70][66]. 
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Many of those who are not obese by traditional weight criteria may 
have an increased percentage of body fat distributed predominantly 
in the abdominal region.  Ketoacidosis is infrequent in this type of 
diabetes; when seen it usually arises in association with the stress 
of  other illness such as infection .  
The risk of developing Type 2 diabetes increases with age, 
obesity, and lack of physical activity . It occurs more frequently in 
women with prior GDM and in individuals with hypertension or 
dyslipidaemia .Some patients who present with a clinical picture 
consistent with Type 2 diabetes have auto antibodies similar to 
those found in Type 1 diabetes, and may masquerade as Type 2 
diabetes if antibody determinations are not made. Patients who are 
non–obese or who have relatives with Type 1 diabetes and who are 
of Northern European origin may be suspected of having late onset 
Type 1 diabetes. 
COMPLICATIONS OF DIABETES MELLITUS 
Acute complications 
Diabetic ketoacidosis 
Diabetic nonketotic, hyperosmolar coma 
Hypoglycemia 
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CHRONIC COMPLICATIONS 
Microvascular 
Retinopathy 
Nephropathy 
Neuropathy 
Macrovascular 
Cerebrovascular  
Cardiovascular  
Peripheral vascular disease 
MICROVASCULAR COMPLICATIONS 
Microvascular complications are specific to diabetes and do    
not occur without longstanding hyperglycaemia. Other metabolic, 
environmental   and genetic factors are undoubtedly involved in 
their pathogenesis. 
Both T1DM and T2DM are susceptible to microvascular 
complications, although patients with T2DM are older at 
presentation and may die of macrovascular disease before 
microvascular disease is advanced. 
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The duration of diabetes and the quality of diabetic control 
are important determinants of microvascular disease but, because of 
other individual factors, do not necessarily predict their developent 
in individual patients.Different microvascular complications are 
commonly associated in individual patients, but their prevalence as 
a function of the duration or severity of diabetes may differ 
markedly.  
Background retinopathy is rare before 5 years of diabetes but 
its prevalence increases steadily thereafter to affect over 90% of 
patients after 20 years. After several years of diabetes, the risk of 
proliferative changes is about 3% of patients per year, with a 
cumulative total of over 60% after 40 years. 
Diabetic nephropathy affects 20-40% of patients with T1DM, 
particularly those presenting before puberty and possibly those with 
an inherited tendency to hypertension. T2DM patients are also 
susceptible to nephropathy. 
Over 40% of subjects with T1DM survive more than 40 years, 
half of them without developing significant micro-vascular 
complications.  
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PATHOPHYSIOLOGY OF MICROVASCULAR DISEASE 
In diabetes, the microvasculature shows both functional and 
structural abnormalities. The structural hallmark of diabetic 
microangiopathy is thickening of the capillary basement membrane.  
The main functional abnormalities include increased capillary 
permeability, blood flow and viscosity, and disturbed platelet 
function. These changes occur early in the course of diabetes and 
precede organ failure by many years. 
Many chemical changes in basement membrane composition 
have been identified in diabetes, including increased type IV 
collagen and its glycosylation products. In patients with poorly 
controlled diabetes, even of short duration, blood flow is increased 
in many tissues including skin, retina and kidney. In the latter this 
is reflected by an elevated glomerular filtration rate. Increased 
capillary permeability is manifested in the retina by leakage of 
fluorescein and in the kidney by increased urinary losses of 
albumin which predict eventual renal failure. Both defects probably 
reflect a generalized vascular abnormality which may also involve 
the intima of the large vessels. 
Platelets from diabetic patients show an exaggerated tendency 
to aggregate, perhaps mediated by altered prostaglandin 
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metabolism[71] . Plasma and whole blood viscosity are increased 
whereas red blood cell deformability is decreased in diabetes.  
These defects together with the platelet abnormalities may 
cause stasis in the microvasculature, leading to increased 
intravascular pressure and to tissue hypoxia. The production by 
endothelial cells of von Willebrand factor and endothelial derived 
relaxing factors (mainly nitric oxide) may also be abnormal in 
diabetes and could contribute to tissue damage. 
BIOCHEMICAL BASIS OF MICROVASCULAR DISEASE 
Prolonged exposure to elevated glucose concentrations 
damages tissues by causing either acute, reversible metabolic 
changes (mostly related to increased polyol pathway activity and 
glycosylation of proteins) or cumulative irreversible changes in 
long lived molecules (formation of advanced glycosylation end 
products /AGE/ on matrix proteins such as collagen and on nucleic 
acids and nucleoproteins). In insulin independent tissues (nerve, 
lens, retina) hyperglycaemia causes elevated tissue glucose levels.  
The enzyme aldose  reductase  catalyses the reduction of 
glucose to its polyol, sorbitol, which is subsequently converted to 
fructose. Sorbitol does not easily  cross cell membranes and its 
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accumulation may cause damage by osmotic effect (e.g. in the 
lens). In addition, increased sorbitol production is partly 
responsible for tissue depletion of myoinositol, a molecule 
structurally related to glucose. Hypergylcaemia itself  inhibits 
myoinositol uptake into cells. Animal studies indicate that tissue 
myoinositol depletion may cause abnormalities on peripheral nerve 
function.  
ADVANCED GLYCOSYLATION END PRODUCTS 
In long lived molecules early glycosylation products slowly 
and irreversibly form complex cross-linkings termed advanced 
glycosylation end products (AGE). Pathological consequences of 
AGE cross linking include covalent binding of proteins (e.g. LDL, 
albumin and IgG) to vessel walls; crosslinking of matrix 
components in vessel walls causing resistance to enzymatic 
degradation; and disturbed three-dimensional structure and altered 
binding of anionic proteoglycans  which influence charge on the 
vessel wall and its interaction with blood-borne protein. Monocyte-
macrophages have a high affinity receptor for AGE and binding of 
AGE may release  cytokines(TNF, IL-1)  and inflammatory 
reactions inside the vessel wall followed by atherosclerotic process. 
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PATHOGENESIS OF  DIABETIC RETINOPATHY 
Histologically the earliest lesion is thickening of the capillary 
basement membrane. On fluorescein angiography the first 
abnormality is the capillary dilatation. Localised capillary 
dilatation is called microaneurysm. Microaneurysm may give rise to 
haemorrhage or exudate. Vascular occlusion, initially of capillaries 
and later of arteries and veins, leads to nonperfusion areas of retina. 
Large ischaemic areas are the stimulus of new vessel formation[1].  
STAGES OF DIABETIC RETINOPATHY 
Background retinopathy  
Capillary dilatation (later with leakage) 
Capillary occlusion  
Microaneurysms  
Blot haemorrhages and lipid rich hard exudates. 
 Preproliferative retinopathy  
Cotton-wool spots (retinal ischemia) 
Venous abnormalities (loops, beading and reduplication)  
Arterial abnormalities (variation of caliber, narrowing of 
segments)     
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Intraretinal microvascular abnormalities (clusters of dilated    
abnormal capillaries lying within the retina). 
Proliferative retinopathy 
  New vessels arise in the periphery and/or on the optic disc, 
eventually with a fibrous tissue covering. The visual complications 
are caused by vitreous retraction which leads to haemorrhage and to 
traction and detachment of the retina.  
Maculopathy  
 Heralded by rings of hard exudates approaching the fovea. 
Maculopathy occurs mostly in T2DM and can cause severe visual 
loss. 
Thrombotic glaucoma is due to new vessels and fibrous tissue 
proliferating in the angle of the anterior chamber, preventing 
drainage of the aqueous. It is associated with rubeosis iridis 
(neovascularisation of the iris) and causes severe pain and 
irreversible blindness 
DIABETIC NEPHROPATHY 
Albuminuria in diabetic nephropathy is due to glomerular 
capillary damage and reflects generalised damage to the 
microcirculation and large vessels, too. Nephropathic patients have 
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an increased incidence of retinopathy and a ten-fold increase in 
cardiovascular mortality which is the major cause of death in 
nephropathic T2DM patients. 
Diabetic nephropathy is defined by persistent albuminuria 
(>300 mg/day), declining glomerular filtration rate and rising blood 
pressure. Established nephropathy follows several years of incipient 
nephropathy, characterised by microalbuminuria (30 – 300 mg/day). 
In T1DM, nephropathy develops in about 35% of cases, 
especially in males and in those whose diabetes presents before the 
age of 15 years. The incidence of nephropathy peaks after 15-16 
years of diabetes and declines thereafter. In T2DM prevalence of 
nephropathy about 10%. 
The prevention of diabetic nephropathy: excellent diabetes 
control, agressive antihypertensive treatment, ACE inhibition 
(without hypertension,too) 
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METHODS & METHODOLOGY  
Study centre : Rajiv Gandhi Government General Hospital, 
Chennai – 3 
 Study duration  : 6 months     
 Study design : Case control study. 
Sample size : 100 patients ; 50 controls. 
 INCLUSION CRITERIA 
Patients with newly diagnosed Diabetes mellitus attending  
Diabetology  OPD  and those who are admitted to the medical 
wards with complications of Diabetes Mellitus. 
EXCLUSION CRITERIA 
Infections: Tuberculosis,HIV.  
Malignancy  
Cirrhosis  
Inflammatory bowel disease  
Patient on ATT, OCP, Valproate,  Penicillamine, Iron supplements  
Pregnancy  
Sickle cell disease 
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 DATA COLLECTION METHODS : 
Collection of data as per proforma with consent from patients 
with diabetes      mellitus in the Institute of Internal Medicine 
wards & in diabetology OP 
SELECTION CRITERIA 
Diabetes 
Diagnostic criteria[ 32]. 
 Symptoms of diabetes mellitus plus random blood glucose 
concentration 11.1mmol/l (200mg/dl) or 
 Fasting plasma glucose 7mmol/l (126mg/dl) or 
 HbA1c >6.5% or 
 2 –hour plasma glucose 11.1mmol/l (200mg/dl) during an oral 
glucose tolerance test. 
Random is defined as without regard to time since the last 
meal. Fasting is defined as no caloric intake for at least 8 h. The 
test should be performed in laboratory certified according to A1C 
standards of the Diabetes Control and Complications Trial. The test 
should be performed using a glucose load containing the equivalent 
of 75 g anhydrous glucose dissolved in water, not recommended for 
routine clinical use. In the absence of unequivocal hyperglycemia 
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and acute metabolic decompensation, these criteria should be 
confirmed by repeat testing on a different day.  
SYSTEMIC HYPERTENSION 
Patients with Systolic BP > 130 & Diastolic BP > 80 mmHg 
OBESITY  
Patients with BMI  >  25 Kg/sq.m. 
DYSLIPIDEMIA 
Total Cholesterol  > 240 mg/dl 
LDL – Cholesterol > 130 mg/dl 
HDL – Cholesterol < 40 mg/dl(males) ; < 50 mg/dl (females) 
Triglycerides > 150 mg/dl 
MICROVASCULAR COMPLICATIONS 
Retinopathy – Retinal changes in fundus examination. 
Nephropathy – Presence of Microalbuminuria in urine. 
Neuropathy – Symptoms ,Signs & NCS Abnormalities. 
MACROVASCULAR COMPLICATIONS 
Coronary heart disease – History, ECG, TMT & ECHO 
Abnormalities. 
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Peripheral vascular disease – Examination & Doppler Study. 
Cerebro vascular accident – History, Examination & Imaging Study. 
STATISTICAL ANALYSIS 
Following statistical methods have been employed in the 
present study. 
Independent samples ‘t’ test-Unpaired. 
Independent samples ‘t’ test-Paired. 
One-way Analysis of Variance (ANOVA). 
SPSS Version 13 
EXCEL 2010 
The study was approved by ethics committee of the hospital. 
ZINC ESTIMATION:[58,66] 
Method – calorimetric method: 
Principle: Zinc is an alkaline medium reacts with nitro-paps 
to form a purple  coloured complex.Intensity of the complex formed 
is directly proportional to  the amount of zinc present in the sample. 
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 Zinc + nitro-paps          purple colour complex 
NORMAL REFERENCE VALUES 
serum-60-120micro gram/dl. 
urine-100-1000micro gram/24 hrs. 
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OBSERVATION AND RESULTS 
Table 1:  Age incidence 
Chart showing age incidence in years: 
 
In the study group of 100 patients with Diabetes,35% were 
seen in the age group of 51-60 years,24% were seen in the age 
group of 41-50 years.Maximum incidence-35% was seen in the age 
group of 51-60 years. 
Age(years) No.of patients % 
10 to 20 4 4 
21 to 30 11 11 
31 to 40 13 13 
41 to 50 24 24 
51 to 60 35 35 
61 to 70 8 8 
>70 5 5 
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Table 2: Age and sex distribution 
Total Male Female 
Age 
No. % No. % No. % 
10  to 20 4 4 3 75 1 25 
21 to 30 11 11 8 72 3 28 
31 to 40 13 13 9 69 4 31 
41to 50 24 24 17 70 7 30 
51 to 60 35 35 22 62 13 38 
61to 70 8 8 5 62 3 38 
>70 5 5 2 40 3 60 
 
Chart showing age and sex distribution 
 
In the study group of 100 patients with DM, 66% were males, 
34% were females. Male :female ratio-1.9:1. 
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Table: 3 Type of diabetes 
  
  Total Male Female 
No. No.  % No.  % 
Type 1 15 11 73 4 27 
Type 2 85 55 65 30 35 
 
Chart showing the distribution of type of diabetes: 
 
In the study group of 100 patients with DM,85%  belonged to 
Type 2 DM,of which 65% were males,35% females.Patients with 
Type 1 DM formed 15%,of which 73% were males,27% were 
females.        
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Table: 4   Symptomatology 
Symptomatology Total % 
Polyuria 28 28 
Polydipsia 32 32 
Polyphagia 26 26 
Chestpain 6 6 
Breathlessness 9 9 
Visualdisturbance 21 21 
Oliguria 7 7 
Chart showing the various symptomatology 
 
In our study, polydipsia was the most common symptom, 
followed by polyuria,polyphagia,visual disturbances &oliguria. 
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Table :5   Duration of diabetes 
Total Male Female 
Duration 
No. % No. % No. % 
New 34 34 21 61 13 39 
<5 14 14 9 64 5 36 
5-10yrs 37 37 23 62 14 38 
>10 15 15 13 86 2 14 
Chart  showing the  duration of diabetes 
 
In our study, 34% patients were newly diagnosed DM,of 
which 61% were males,39% were females.14% patients were 
diabetics of <  5years duration.37% had a duration of 5 to 10 years 
and 15% had diabetes of more than 10 years. 
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Table: 6   Risk factors 
Total Male Female 
Risk factors 
No. No. % No. % 
Systemic hypertension 26 19 73 7 27 
Dyslipidemia 11 7 64 4 36 
Smoking 22 22 100 0 0 
Alcoholism 13 13 100 0 0 
Obesity 23 16 70 7 30 
Total 95 77  18  
Chart showing the various risk factors among patients 
 
In our study, most common risk factor was systemic 
hypertension  26%, followed by obesity[23%], smoking[22%], 
alcoholism[13%] & dyslipidemia[11%]. 
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Table: 7     Microvascular complications 
Total Male Female 
 
No. No. % No. % 
Retinopathy 22 20 91 2 9 
Neuropathy 11 9 82 2 18 
Nephropathy 28 22 79 6 21 
Total 61 51  10  
Chart showing the various microvascular complications 
 
 The  most common micro vascular complication was 
nephropathy [  28%]  of patients,followed by Retinopathy [22%] of  
patients. 
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Table: 8    Macrovascular complications 
Total Male Female  
 
No. No. % No. % 
CAD 10 7 70 3 30 
CVA 11 9 82 2 18 
PAD 2 2 100 0 0 
Total 23 18  5  
 
C hart showing the various macrovascular complications 
 
In our study, the most common macro vascular complication 
was stroke, which was present in 11% patients,followed by 
coronary artery disease,seen in 10% patients. 
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Table: 9     Treatment regimen 
Total Male Female  
 No. No. % No. % 
Insulin 16 12 75 4 25 
OHA 84 54 64 30 36 
Total 100 66  34  
Chart showing the  treatment regimen  
 
In our study, 84% patients was on treatment with OHA, out of 
which 64% were male,36% were female.16% patients were getting 
insulin treatment. 
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Table: 10 Comparison of serum zinc levels between  patients and 
control 
Parameter Subject  (n=100) 
Control  
(n=50) P value 
Mean Age 47 48 0.6379 
Mean Zinc Levels 63.08 75.48 0.0001 
In our study, 100 patients when compared to 50 controls had 
significant lower levels of zinc with a p value of <0.0001. 
Table:11 Serum zinc levels in males and females 
Male Female 
Zinc Levels[µg] Total 
No. % No. % 
10 - 20 2 2 100 0 0 
21- 30 4 4 100 0 0 
31 - 40 8 8 100 0 0 
41- 50 14 11 78 3 22 
51 - 60 19 12 63 7 37 
61 - 70 27 15 55 12 45 
71 - 80 11 7 63 4 37 
81 - 90 6 2 33 4 67 
91- 100 4 1 25 3 75 
101 - 110 4 3 75 1 25 
>110 1 1 100 0 0 
TOTAL 100 66  34  
In our study, 100 patients when compared to 50 controls had 
significant lower levels of zinc with a p value of <0.0001. 
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Table:11 Serum zinc levels in males and females 
Male Female 
Zinc 
Levels[µg] Total 
No. % No. % 
10 - 20 2 2 100 0 0 
21- 30 4 4 100 0 0 
31 - 40 8 8 100 0 0 
41- 50 14 11 78 3 22 
51 - 60 19 12 63 7  
Chart showing the  serum zinc levels in males and females   
 
In our study, it was found that 47 people had low levels of 
Zinc (<60 micrograms) of which majority(19) belonged to the 51-
60 micrograms category. 2 persons had values in the range of 10-20 
µg .  
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Table:12  Zinc level in nephropathy 
Nephropathy 
Males Females Zinc level (µg) 
Total 
No. % No. % 
0-20 1 1 100 0 0 
20-40 7 7 100 0 0 
40-60 15 10 75 5 25 
60-80 5 4 80 1 20 
Chart showing zinc level in nephropathy  
 
In our study, patients with nephropathy formed 28%,of which 
82% had low serum zinc level[<60 micro gram] 
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Table:13    Zinc level in Retinopathy 
Retinopathy 
Males Females Zinc level (µg) 
Total 
No. % No. % 
0-20 1 1 100 0 0 
20-40 7 7 100 0 0 
40-60 10 8 80 2 20 
60-80 4 4 100 0 0 
Chart showing  zinc level in retinopathy 
 
In our study, patients with Retinopathy formed 22%,of which 
81% had low serum zinc levels[<60 micro gram]. 
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Table: 14   Zinc level in neuropathy 
Neuropathy 
Males Females Zinc level (µg) 
Total 
No. % No. % 
20-40 3 3 100 0 0 
40-60 7 5 71 2 29 
60-80 1 1 100 0 0 
Chart showing  zinc level in neuropathy  
 
In our study, patients with neuropathy formed 11%,of which 
90% had low serum zinc levels.[<60 micro gram] 
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Table: 15  Zinc level in CAD 
Coronary artery disease 
Males Females Zinc level (µg) 
Total 
No. % No. % 
0-20 1 1 100 0 0 
20-40 4 4 100 0 0 
40-60 4 2 50 2 50 
60-80 1 0 0 1 100 
Chart showing  zinc level in CAD  
 
In our study, patients with CAD formed10%, of which 90% 
had low serum zinc levels. 
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Table: 16    Zinc level in CVA and PAD 
Cerebro vascular  
disease 
Peripheral  
Artery disease 
Males Females Total 
Zinc level 
(µg) 
Total 
No. % No. % M F 
20-40 3 3 100 0 0 1 0 
40-60 6 4 66 2 34 1 0 
60-80 2 2 100 0 0 0 0 
Chart showing  zinc level in CVA and PAD 
 
In our study, patients with CVA formed 11%,of which 81% 
had low serum zinc levels.Patients with PAD formed 2%, all had 
low serum zinc levels. 
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Table: 17  HbA1c level in males and females 
Males Females 
HbA1c level 
% Total 
No. % No. % 
5-5.5 2 1 50 1 50 
5.6-6 36 22 61 14 39 
6.1-6.5 28 17 60 11 40 
6.6-7 19 15 78 4 22 
7.1-7.5 9 7 77 2 23 
>7.5 6 4 66 2 34 
  Chart showing  HbA1C level in males and females 
 
In our study, 36% had HbA1c level in the range of 5.6 -
6,followed by 28%  who had HbA1C Level in the range of 6.1-6.5. 
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Table: 18 Correlation of zinc level in micro &macro vascular 
complications 
Parameter Microvascular Macrovascular 
No.of patients 61 23 
Mean Zn level (µg) 46.52 43.86 
In our study patients with micro vascular complications,  
there was no significant variaton in serum zinc levels in each 
groups [retinopathy,nephropathy&neuropathy] with  p value of 
0.8431.In Patients with macro vascular complications also, there 
was no significant variation in serum zinc level in each 
groups[CAD,CVA&PAD] with p value of 0.4537.  
Table: 19  Comparision of zinc level and HbA1c level 
HbA1c level Total No.of patients Mean Zinc level 
5-5.5 2 78 
5.6-6 36 70 
6.1-6.5 28 64 
6.6-7 19 52 
7.1-7.5 9 50 
>7.5 6 46 
In our study, there was a significant relation between serum 
HbA1C level and zinc levels.Patients with poor glycaemic control 
had low serum zinc level compared to patients with good glycaemic 
control,which was statistically significant with p value of <0.0001. 
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Table 20: Comparision of serum zinc level with duration of DM 
Duration No.of patients 
Serum mean zinc 
level 
Newly 
diagnosed 
34 69.74 
1-4 years 14 69.78 
5-10 years 37 56.16 
>10 years 15 51.93 
 
 
 
p 
value<0.05 
Patients with long standing diabetes had lower zinc levels 
than newly diagnosed patients, which was found to be statistically 
significant with p value   < 0.0035. 
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DISCUSSION 
The total number of patients analysed were 100,out of which 
66% were males and 34% were females.The prevalence of diabetes 
was found to increase as the age advances.  
This finding correlated with  the study done by Ahuja 
mms[1996].Most of the patients in the study group were in the age 
group of 51-60 years[35%].85%  of patients had type 2DM,of 
which 65% were males and 35% were females.  
26% of patients in our study group had systemic 
hypertension, obesity was found in 23% of  patients. Other risk 
factors like smoking [22%], alcohol [13%]& dyslipidemia [11%] 
were also present. 
Of the 100 patients in the study, 84 were on Oral 
Hypoglycemic Agents and the remaining 16 were on Insulin 
therapy. 
23 % of the subjects had macrovascular complications in the 
form of CAD (10%), CVA (11%) and PAD(2%) 
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61% of the subjects had Micro vascular complications in the 
form of Nephropathy (28%), retinopathy (22%) and Neuropathy 
(11%) 
The Mean Value for Serum Zinc levels in healthy individuals 
studied was within normal range as established by Study of Zinc 
Homeostasis in Humans [72]. Likewise our study showed decreased 
levels of Serum Zinc in Diabetic individuals compared to normal 
subjects. The minimum Zinc value found in the present study was 
similarly reported by a number of other studies [73], [74], [75] 
It was also found in our study that compared to the newly 
diagnosed, patients with long standing Diabetes Mellitus had lower 
levels of Zinc.    
Among the subjects with microvascular complications, 90% 
with neuropathy, 82% of those with nephropathy, 81% with 
retinopathy had low serum Zinc levels. 
But there was no significant statistical variation in serum zinc 
levels between the various micro vascular complications. 
Among the subjects with macrovascular complications 100% 
with PAD, 90% with CAD and 81% with CVA had lower levels of 
Zinc. 
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But there was nosignificant statistical variation  in serum zinc 
levels between the various macro vascular complications. 
Similarly there was no significant statistical variation  in 
serum zinc levels between the macro vascular and microvascular 
complications. 
There was a significant negative correlation between HbA1C 
and serum Zinc levels. 
Also, patients with poor glycemic control had lower Zinc 
levels compared to the subjects with a better glycemic control. This 
correlated with the conclusions of a study done by Al-Maroof   and 
Al-Sabatti  in 2006 for the Ministry of Health, Iraq. 
 LIMITATIONS OF THE STUDY 
 Zinc Supplementation was not done hence its effect on the 
subjects could not be ascertained. 
 Urinary and Stool Zinc levels were not measured. 
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CONCLUSION 
 Diabetes is more commonly seen in males (66%) compared to 
females (34%). 
 Diabetes is commonly diagnosed in the age group of 51-60 yrs. 
 Among those with Diabetes, the microvascular complications 
(61%) occur more often than  the macrovascular 
complications (23%). 
 Nephropathy (28%) is the commonest microvascular 
complication closely followed by Retinopathy (22%). 
 Diabetic individuals have significantly lower levels of Zinc 
when compared to normal healthy individuals. 
 Patients with long standing DM have lower Zinc levels than 
those who are newly diagnosed. 
 Patients with poor glycemic control have lower Zinc levels 
compared to the subjects with a better glycemic control. 
Zinc supplementation may have a therapeutic role in control 
and prevention of complications in DM. Further studies are needed 
to clarify this aspect. 
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PROFORMA 
NAME 
AGE 
SEX 
I.P NO 
OCCUPATION & ADDRESS 
DURATION OF  DIABETES MELLITUS: 
 
SYMPTOMS  
 Polyuria    Oliguria                   Visual disturbances 
 Polydypsia     Puffiness of Face        Weight loss/gain 
 Polyphagia     Swelling of legs         High coloured urine 
Giddiness       Anorexia                    Headache/ LOC/  
 Seizures         Altered sensorium  
  Chest Pain     Vomiting/Hiccup        Sensory disturbances 
  Palpitation     Easy fatiguability        Poor wound healing  
  Leg ulcers 
 Dyspnea          Altered bowel habit    Limb weakness 
 Fever               Dysuria                     Abdominal Pain 
PAST HISTORY 
• * Hypertension         * Renal disorders        *CAD 
• * CVA                      *Seizure disorder         * Pulmonary TB  
• *Surgical illness       * Blood transfusion     *Hypoglycemic  attacks  
•  *Thyroid Disorder   * Liver disorders                                
•  * Drug intake-  Ethambutol ,Penicillamine, Iron, Dietary fibres, Sodium     
    valproate  
PERSONAL HISTORY 
•     Smoking   
•     Alcoholism    
•     Drug abuse         
•     STD  
•     Prolonged Starvation  
•     Exercise 
ANTHROPOMETRY  
• Ht:            cms Wt:               kgs  BMI: 
• Hydration Status  JVP 
FUNDUS   
• Features of Thyroid Disorders: 
• Features of Cushing’s Syndrome: 
 
• Pulse:   
• Blood Pressure:  
(Stage of Hypertension) 
SYSTEMIC EXAMINATION: 
CVS:  
RS:  
Abdomen:          
CNS:    
INVESTIGATIONS 
• Hb:             TC:  DC:  P-     L-         E-         M- Plt: 
• ESR                               : 
• Blood Glucose Fasting :             Blood Glucose PP: 
• Blood Urea                     : 
• Serum Creatinine    : 
• Uric Acid                 :  
• Serum Electrolytes : Na+  K +  HCO3-  
• Lipid Profile: 
• Total Cholesterol :     HDL : 
• Triglycerides :     LDL : 
• Chol: HDL Ratio : VLDL : 
• Liver function test: 
• Bilirubin Total : 
               Direct : 
• SGOT : 
• SGPT :  
• Sr. Alkaline Phosphatase : 
• Total Protein : 
         Albumin : 
         Globulin : 
Urine examination: 
• Micro Albumin :    Deposits: 
• Albumin : 
• Sugar : 
• ECG: 
X-ray chest pa view : 
• Echo cardiogram : 
• USG abdomen :  
• HIV serology : 
• CT brain ( if indicated)     : 
• Carotid & vertebral doppler  (if indicated) : 
• Nerve conduction study (if indicated) : 
• Serum  zinc level: 
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1 GOVINDARAJ 57 M N P P P A A A A A A A 2 NIL OHA A A P A A A A A A A A 112 152 6 56
2 SUBBU 51 M N P P P A A A A A A A 2 NIL OHA A A P A A A A A A A A 142 181 6.5 62
3 KOILRAJ 32 M N P P P A A A A A A A 2 NIL OHA A A A A A A A A A A A 121 177 6.3 77
4 VENKATRAM 46 M O A A A A A A A A A A 2 10 INS A A A A A A A A A A A 156 233 7.5 52
5 ARUMUGAM 48 M O A A A A A A A A A A 2 5 OHA A A A A A A A A A A A 132 246 7.3 64
6 ARUNACHALAM 23 M N P P P A A A A A A A 1 NIL INS A A A A A A A A A A A 160 252 8.2 45
7 RAJA 42 M O A A P A A A A A A A 2 3 OHA A A A A A A A A A A A 144 198 7.6 48
8 KANNAN 56 M N P A P A A A A A A A 2 NIL OHA A A A A A A A A A A A 129 160 6.9 50
9 RASU 69 M O A A A A A A A P A A 2 16 OHA A A P A A A A A P A A 119 198 6.8 55
10 SUBRAMANI 51 M N P P P A A A A A A A 2 NIL OHA A A A A A A A A A A A 154 211 7.2 79
11 MAHENDRAN 32 M N P P P A A A A A A A 2 NIL OHA P A A A A A A A A A A 166 208 7 80
12 LAKSHMI 42 F N P P P A A A A A A A 2 NIL OHA A A P A A A A A A A A 134 186 6.7 68
13 BAGYAVADHI 26 F O A A A A A A A A A A 1 10 INS A A A A A A A A A A A 155 206 6.1 61
14 MURUGAN 72 M O A A P A A A A A A A 2 25 OHA P A A A A A A A A A A 134 178 6.8 59
15 KRISHNAN 39 M N P P P A A A A A A A 2 NIL OHA A A A A A A A A A A A 143 173 5.9 59
16 KADHIRESAN 61 M O A A A A A P A A P A 2 14 OHA A A A A A A A A A A P 119 165 6.7 61
17 MARY 48 F N P P P A A A A A P A 2 NIL OHA A A P A A A A A A A A 124 149 5.9 69
18 RAVI 14 M N P P A A A A A A A A 1 NIL INS A A A A A A A A A A A 133 167 7.2 29
19 VIJAYASANKARAN 49 M O A A A A A A A A A A 2 8 OHA A A A A A A A A A A A 124 154 6.1 79
20 GOWRIAMMAL 59 F N A A P A A A A A A A 2 NIL OHA A A P A A A A A A A A 169 244 8.9 51
21 DHANAPAL 34 M O A A A P P A A A A A 1 20 INS P A A A A A P A A A A 145 176 6.7 34
22 MARKANDEYAN 51 M N P A P A A A A A A A 2 NIL OHA A A A A A A A A A A A 140 189 6.2 77
23 KUPPUSAMY 68 M O A A A A A A A A A A 2 15 OHA A A P A A A A A A A A 117 134 5.8 67
24 THILAGAVATHY 49 F N P P A A A A A A A A 2 NIL OHA A A A A A A A A A A A 129 177 6.9 70
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25 RAMASAMY 53 M O A A A P P A A A A A 2 13 OHA P A P A A A P A A P P 144 189 6.3 38
26 SENTHILNATHAN 22 M O A A A A A A A A A A 1 5 INS A A A A A A A A A A A 132 176 6 69
27 RAJA SEKAR 43 M O A A A P A P A A P A 2 7 OHA A P A A P A P A A P P 126 188 6.9 44
28 ROSELIN MARY 37 F N P P A A A A A A P A 2 NIL OHA A A P A A A A A A A A 129 155 5.9 89
29 ANTONY 41 M N A A P A A A A A A A 2 NIL OHA A A A A A A A A A A A 119 177 6.4 51
30 FATHIMA BEE 59 F N P P P A A A A A A A 2 NIL OHA A A P A A A A A A A A 168 210 8 50
31 PARAMESWARAN 18 M N P P P A A A A A A A 1 NIL INS A A A A A A A A A A A 188 266 9 46
32 RAJAIYAH 59 M N A A A A A A A A P A 2 NIL OHA A P A A A A A A A A A 135 176 7 107
33 VARALAKSHMI 38 F N P P P A A A A A P A 2 NIL OHA A A P A A A A A A A A 121 155 6.3 78
34 PERUMAL 49 M N P P A A A A A A A A 2 NIL OHA A A P A A A A A A A A 119 145 6 80
35 GANDHIMATHI 55 F N A A A A A A A A A A 2 NIL OHA A A A A A A A A A A A 119 178 7.1 51
36 KUMARAN 25 M O A A A A A A A A A A 1 9 INS A A A A A A A A A A A 110 143 5.8 62
37 CHINNAMA 67 F O A A A P P A A A A A 2 7 OHA A A A A A A P A A P A 142 177 6.9 42
38 AYYAPAN 29 M N P P P A A A A A A A 1 NIL INS A A A A A A A A A A A 131 158 6.2 70
39 MALLIGA 46 F N P P P A A A A A P A 2 NIL OHA A A A A A A A A A A A 139 171 6 109
40 RAMALINGAM 56 M N P A A A A A A A A A 2 NIL OHA A A P A A A A A A A A 122 155 8.1 38
41 KAMARAJ 42 M N P P P A A A A A P A 2 NIL OHA A A A A A A A A A A A 119 149 6 70
42 DHANAM 39 F O A A A A A A A A A A 2 1 OHA A A A A A A A A A A A 110 158 6.1 95
43 VENKATACHALAM 51 M O A A A P A P A A P A 2 16 OHA P P P A A A P A A P P 155 190 7.3 18
44 GANESAN 52 M O A A A A A A A A A A 2 11 OHA A A P A A A A A A A A 118 175 6.2 94
45 MOORTHY 54 M O A A A A A A P A A A 2 7 OHA A P P P A P A A A A A 102 152 6.8 25
46 SANKARI 19 F O A A A A A A A A A A 1 13 INS A A A A A P A A A A A 114 137 5.3 55
47 SASIKALA 29 F O A A A A A A A A A A 1 11 INS A A A A A A A A A A A 102 130 5.8 79
48 SIVAKUMAR 38 M N P P P A A A A A P A 2 NIL OHA A A P A A A A A A A A 116 139 6 112
49 MANIKANDAN 41 M N A P P A A A A A A A 2 NIL OHA A P P A A A A A A A A 127 164 6.3 62
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50 AANDAWAR 78 M O A A A A A A A A A A 2 5 OHA A A A A A A A A A A A 119 169 6 54
51 MURUGESWARI 53 F N P P P A A A A A A A 2 NIL OHA A A A A A A A A A A A 104 149 6.9 53
52 BALAMURUGAN 23 M O A A A A A A P A A A 1 13 INS P A A P A P A A A A A 110 166 6.4 39
53 JAYALAKSHMI 51 F N P P P A A A A A A A 2 NIL OHA A A A A A A A A A A A 102 155 5.9 90
54 VIGNESHWARAN 17 M O A A P A A A P A A A 1 12 INS A A A P A P A A A A A 117 169 6.7 41
55 SARASWATHY 65 F O A A A A A A A A A A 2 6 OHA A A A A A A A A A A A 123 147 5.9 69
56 ROSAMMAL 57 F O A A A A A A A A A A 2 2 OHA A A A A A A A A A A A 111 136 6.1 68
57 THIYAGARAJAN 59 M O A A A A A A A A A A 2 3 OHA A A A A A A A A A A A 109 146 5.8 62
58 AYYASAMY 57 M O A A A A A A P A P A 2 11 OHA A A P P A P A A A A A 125 189 6.8 26
59 PAPPAMMAL 69 F O A A A A A A A A A A 2 6 OHA A A A A A A A A A A A 112 155 6.3 64
60 BALAJI 37 M O A A A A A A P A A A 2 5 OHA P P P P P P A A A A A 120 189 7.1 51
61 VIDHYA 41 F O A A A A A A A A A A 2 1 OHA A A A A A A A A A A A 131 167 5.9 68
62 SARAVANAN 43 M O A A A P A P A P A P 2 8 OHA P A A A P P P A P P A 121 149 6.2 31
63 SUDHAKAR 39 M O A A A A A A P A A A 2 6 OHA P A A P P P A A A A A 109 143 5.9 67
64 SANGEETHA 44 F O A A P A A A A P A P 2 5 OHA A A A A A P A A P A A 100 139 6.1 56
65 USHA 51 F N P P P A A A A A A A 2 NIL OHA A A A A A A A A A A A 98 139 5.8 99
66 GOPAL 44 M O A A A P P P A A P A 2 2 OHA A A A A P A P A A P A 122 146 6.1 46
67 SUBRAMANI 51 M O A A A A A A P P P P 2 9 OHA P A A P A P A P P A A 113 142 6 51
68 STALIN 29 M O A A A A A A P A A A 1 16 INS A A A P A P A A A A A 105 138 5.8 69
69 KANNADHASAN 56 M O A A A A A A P P A P 2 7 OHA P A A P A P A P P A A 133 178 6.9 31
70 KASTHOORI 28 F O A A A A A A A A A A 1 5 INS A A A A A A A A A A A 113 166 5.9 99
71 ESWARAN 64 M N P A P A A A A A A A 2 NIL OHA A A P A A A A A A A A 100 132 5.6 78
72 GUNASEKARAN 59 M O A A A A A A P P A A 2 10 OHA P P A P P P A A P A A 101 169 7 46
73 JOTHI 37 F O A A A A A A A A A A 2 2 OHA A A A A A A A A A A A 112 145 6.4 68
74 VARADHARAJAN 49 M O A A P A A A A A P A 2 4 OHA A A A A A P A A A A A 122 150 6.1 59
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75 SEENIAMMAL 79 F O A A A A A A A A P A 2 7 OHA A A A A A A A A A A A 110 146 6.2 79
76 LATHA 47 F O A A A P P P A P P A 2 6 OHA A A A A P P P A P P A 115 139 5.9 56
77 DAMODHARAN 61 M N P P P A A A A A A A 2 NIL OHA P A P A A A A A A A A 112 177 5.6 88
78 KARUNANIDHI 49 M O A A A A A A P A A A 2 9 OHA P P A P P P A A A A A 105 138 6 25
79 THANGIRAMU 52 F N A P P A A A A A P A 2 NIL OHA A A A A A A A A A A A 89 125 6 80
80 ALAGESAN 54 M O A A A A A A A A A A 2 5 OHA P A P P A P A A A A A 95 134 5.8 47
81 PAULRAJ 36 M O A A A A A A P P A P 2 4 OHA P A A P A P A A P A A 86 123 6.1 62
82 AMUDHA 51 F O A A A A A A A A A A 2 1 OHA A A A A A A A A A A A 124 156 6.4 90
83 RAJENDRAN 45 M O A A A A A A P P A A 2 5 OHA P P A P A P A A P A A 92 143 6.2 43
84 GAYATHRI 58 F O A A A P P A A A A A 2 9 OHA A A A A A A P A A P A 109 124 6 61
85 THAMBAIYAAH 53 M O A A A A A A A A A A 2 9 OHA A A A A A A A A A A A 123 145 5.7 89
86 NARASIMAN 59 M O A A A A A A P A P A 2 5 OHA P A A P A P A A A A A 111 135 6 19
87 VENGAYYA 54 M O A A A A A A P A P A 2 8 OHA P P A P P P A A A P A 88 133 6.2 66
88 KANAGA 58 F O A A A A A A A A A A 2 7 OHA A A A A A P A A A A A 97 144 7.2 70
89 AMMAIYAPPAN 51 M O A A A A A A P A P A 2 3 OHA A A A P A P A A A A A 122 168 7 59
90 JAGADEESAN 27 M O A A A A A A A P A A 1 15 INS P P A A A P A A P A A 118 154 6.8 44
91 VIMALA 71 F O A A A A A A A A A A 2 5 OHA A A A A A A A A A A A 129 167 6.2 66
92 ALAGAPPAN 44 M O A A A A A A P A A A 2 5 OHA A P P P A P A A A A A 112 156 6.1 55
93 MANOHARAN 42 M O A A A A A A P P P A 2 2 OHA A A A P A P A A P A A 143 178 7.1 40
94 KARTHIKAMMA 78 F O A A A A A A A A A A 2 6 OHA A A A A A A A A A A A 91 134 5.8 88
95 PALANIVEL 42 M O A A A A A A P A P A 2 5 OHA P P P P P A P A A P A 124 167 6 34
96 RANGANATHAN 53 M O A A A A A P A A P A 2 5 OHA A A A A A A A A A A P 114 153 5.9 61
97 KALYANI 59 F O A A A A A A P A A A 2 8 OHA A A P P A P A A A A A 110 146 6 45
98 RAMAN 34 M O A A A A A A A A A A 2 1 OHA A A A A A A A A A A A 116 132 5.6 110
99 KANNAN 28 M O A A A A A A A A A A 2 1 OHA P A A A A A A A A A A 87 116 5.4 102
PO
L
Y
U
R
I
A
P
O
L
Y
P
H
A
G
I
A
P
O
L
Y
D
Y
P
S
I
A
B
R
E
A
T
H
L
E
S
S
N
E
S
S
C
H
E
S
T
P
A
I
N
O
L
I
G
U
R
I
A
V
I
S
U
A
L
 
D
I
S
T
U
R
B
A
N
C
E
S
S
E
N
S
O
R
Y
 
M
O
T
O
R
 
D
I
S
T
U
R
B
A
N
C
E
S
O
B
E
S
I
T
Y
L
E
G
 
U
L
C
E
R
S
R
E
T
I
N
O
P
A
T
H
Y
C
V
A
M
I
C
R
O
A
L
B
U
M
I
N
U
R
I
A
C
A
D
P
E
R
I
P
H
E
R
A
L
 
A
R
T
E
R
I
A
L
 
D
I
S
E
A
S
E
N
E
U
R
O
P
A
T
H
Y
D
Y
S
L
I
P
I
D
E
M
I
A
A
B
N
O
R
M
A
L
 
R
E
N
A
L
 
F
U
N
C
T
I
O
N
Symptoms Complications
NO NAME AGE SEX
N
E
W
/
O
L
D
T
Y
P
E
D
U
R
A
T
I
O
N
(
Y
E
A
R
S
)
T
R
E
A
T
M
E
N
T
(
O
H
A
/
I
N
S
U
L
I
N
)
S
M
O
K
I
N
G
A
L
C
O
H
O
L
I
S
M
S
Y
S
T
E
M
I
C
 
H
T
F
B
S
P
P
B
S
H
B
A
1
C
S
E
R
U
M
 
Z
I
N
C
 
L
E
V
E
L
(
µ
g
/
d
l
)
100 RANI 54 F O A A A A A A P A A A 2 8 OHA A A A P P P A A A P A 100 135 6.2 57
Name Age Sex Zinc
palani 43 M 70
subbu 47 M 65
Mani 35 M 81
raja 39 M 88
murugan 46 M 69
guru 45 M 70
suganya 41 F 50
selvi 43 F 53
prabhu 52 M 90
senthil 54 M 51
yogesh 56 M 53
mangamma 67 F 81
gopi 69 M 94
manjula 70 F 91
ravi 34 M 82
ram 39 M 70
rajaram 44 M 67
saravanaa 47 M 68
Ramesh 49 M 86
kala 53 F 74
arasi 55 F 85
vijayakumar 61 M 55
anbu 48 M 57
logesh 49 M 71
selvam 50 M 72
azhageshwari 49 F 99
Rani 50 F 85
babu 51 M 75
jahir 53 M 83
vignesh 31 M 59
suresh 33 M 71
keerthana 32 F 64
subulakshmi 39 F 53
muniammal 37 F 63
lakshmi 42 F 93
kamatchi 44 F 95
krishna 57 M 71
karthick 59 M 74
shanthi 36 F 77
rajn 41 M 79
siva 42 M 80
rajasekar 63 M 80
rani 65 F 89
murugeshwari 58 F 77
indira 60 F 87
rakesh 42 M 89
govind 43 M 65
theivanai 49 F 91
ramasamy 55 M 85
vasanthi 46 F 97
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